VMC: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Vulcan Materials CO (VMC)

Vulcan Materials CO

VMC

Held by 2 specialist biotech funds

2 funds opened new positions. Short interest: 4.5% of float.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

3.0/10

2 funds opened new positions

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 2 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus Capital

Eventide Asset ManagementNew

Position Trend

Aug 14, 2025

0 funds

Nov 14, 2025

0 funds

Feb 13, 2026

$48.3M

1 fund

Feb 17, 2026

0 funds

-100% total institutional value over 10 quarters

Short Interest

Short Shares

5.11M

Change

+25.4%

Days to Cover

4.0

% of Float

4.5%

Settlement

Apr 15, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

9 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

VFC1 fund ZTS1 fund ZS1 fund EW1 fund ESI1 fund ADCT1 fund GPN1 fund TFC-PR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer